Next Article in Journal
Notch Signaling Pathway Is Activated in Motoneurons of Spinal Muscular Atrophy
Next Article in Special Issue
Genome-Wide Investigation of Multifocal and Unifocal Prostate Cancer — Are They Genetically Different?
Previous Article in Journal
The -173 G/C Polymorphism of the MIF Gene and Inflammatory Bowel Disease Risk: A Meta-Analysis
Previous Article in Special Issue
Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2013, 14(6), 11402-11423; doi:10.3390/ijms140611402

Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma

1
Department of Urology, Experimental Urology (267), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands
2
Department of Nuclear Medicine (756), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands
3
Department of Urology (659), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 28 April 2013 / Revised: 14 May 2013 / Accepted: 15 May 2013 / Published: 29 May 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [963 KB, uploaded 19 June 2014]   |  

Abstract

Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as diagnostic modality holds great promise for the future, both in detecting localized and advanced disease. Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase inhibitors, which constitutes the current standard treatment for mRCC, needs to be established. View Full-Text
Keywords: CAIX; monoclonal antibody; G250; girentuximab; clear cell renal cell carcinoma; RCC; radioimmunotherapy; imaging CAIX; monoclonal antibody; G250; girentuximab; clear cell renal cell carcinoma; RCC; radioimmunotherapy; imaging
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Oosterwijk-Wakka, J.C.; Boerman, O.C.; Mulders, P.F.A.; Oosterwijk, E. Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma. Int. J. Mol. Sci. 2013, 14, 11402-11423.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top